Live
Clinical OMICsFirst Novel Antifungal for Aspergillus in 20 Years Succeeds in Phase IIIBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 18, 2026Endpoints NewsTreasury weighs screening investments in China biotechBioPharma DivecAMPfield lands $180M to build gut disease drugEndpoints NewsNovo Nordisk expands in China and Czech; Cellares boosts Series D by $50MBioPharma DiveBiogen adds more immune drugs in $1B buyout of secretive startup RaytheraPromega BlogWhat Happens When You Delay an Ebola Vaccine Booster by 18 Months?FierceBiotechcAMPfield harvests $180M series A to advance oral IBD drug licensed from NewsoaraEndpoints NewsIRA's Medicare out-of-pocket cap increased access to drugs, study findsBioWorldVRBPAC adcom to vote on Moderna flu vaccineEndpoints NewsPrepping for peptides
Illumina Jan 24, 2026

Is It Time To Reconsider Illumina (ILMN) After Mixed Multi Year Share Performance? - Yahoo Finance

Is It Time To Reconsider Illumina (ILMN) After Mixed Multi Year Share Performance? - Yahoo Finance

Body unavailable. Use the original source.